Emergent BioSolutions Founder Fuad El-Hibri Dies Weeks After Retirement

Published on :

Emergent BioSolutions Founder Fuad El-Hibri Dies Weeks After Retirement
Published: May 02, 2022 By Alex Keown
Fuad El-Hibri/Courtesy of The Washington Post/Getty Images
Weeks after stepping down from his role as executive chairman of Emergent BioSolutions, company founder and former chief executive officer Fuad El-Hibri has died.
In a brief statement issued by Maryland-based Emergent, El-Hibri died at home last week died at his home, surrounded by family. No cause of death was provided by the company, however, The New York Times reported that the cause of death was related to pancreatic cancer. El-Hibri was 64.
El-Hibri stepped down from his role as executive chairman on April 1. He initially announced his decision at the beginning of the year.
“Creating and leading Emergent has been the honor of my life, and it would not have been possible without the help of our incredible team,” El-Hibri said in a statement when he announced his retirement. “I want to thank everyone at Emergent, past and present, for helping advance our inspiring mission over the past two decades. I could never have imagined the number of lives we would impact, and I will forever be proud of our accomplishments. Emergent is on track…

Creating the Freedom to Innovate and Fail, a Sign of Great Executive Leadership

Published on :

We spoke with Dr. Emad Hassan, Chief Science Officer at Modavar Pharmaceuticals (Modavar), about the importance of effective, impactful leadership that sparks innovation and productivity. Modavar is a wholly-owned subsidiary of Indian pharma giant Cadila Pharmaceuticals. Modavar recently opened a brand new, state-of-the-art, 22,000 square foot manufacturing facility in Frederick, Maryland, adding a prestigious new life science company to the blossoming Frederick biotech hub.

5 Questions with Ken Malone, Co-Founder, and Principal, Early Charm Ventures, LLC.

Published on :

Ken Malone is a co-founder of Early Charm Ventures, a venture studio founded in 2012 in Baltimore (Charm City) that converts science to business. Early Charm specializes in taking brilliant scientific discoveries made at universities and turning them into companies focused on growth. They don’t chase quick exits. They build companies that create sustainable value.

5 Questions with John Newby, CEO, Virginia Bio

Published on :

John Newby is the CEO at Virginia Bio, the statewide non-profit trade association for the life science industry. Approximately 300 companies spanning biopharmaceuticals, medical devices, med tech, diagnostics, digital health, bioinformatics, agriculture, and industrial bio and related fields are based in Virginia, mainly clustered around research universities and medical institutions. Virginia Bio is the sole state affiliate and works closely with key national industry organizations BIO, AdvaMed, MDMA, PhRMA and We Work for Health.

5 Questions with Martha Schoonmaker, Executive Director, Pinkney Innovation Complex for Science and Technology at Montgomery College (PIC MC)

Published on :

Martha Schoonmaker is the first Executive Director for the PIC MC Foundation, the entity that develops, manages and markets the Germantown campus on behalf of Montgomery College for company locations. PIC MC is an integrated academic, business, and research campus and is the only community college with a hospital, Holy Cross Germantown Hospital, located as the anchor resident partner.

5 Questions with Brian Hahn, Senior Vice President & CFO, GlycoMimetics

Published on :

Mr. Hahn has more than 15 years of senior financial and operations experience in emerging organizations. He joined GlycoMimetics in 2010. Previously, Mr. Hahn served as executive director of finance at Middlebrook Pharmaceuticals (formerly Advancis Pharmaceutical), a publicly-traded specialty pharmaceutical company.

5 Questions with Amy Adams, Executive Director of the Institute for Biohealth Innovation at George Mason University

Published on :

As Executive Director of the Institute for Biohealth Innovation at George Mason University, Amy Adams is responsible for nurturing and advancing biohealth research and innovation interests of more than 250 faculty and thousands of students who represent a broad range of academic disciplines. Her role includes fostering partnerships with industry, healthcare, government, and academic partners.

5 Questions with Mike O’Mara, VP of Industrial Business Services, Miltenyi Biotec

Published on :

Mike O’Mara has more than 27 years of experience in biopharmaceutical contract manufacturing encompassing microbial, mammalian, and cell/Gene therapy manufacturing processes ranging from Preclinical/Phase I through Commercial.